[Treatment of non-dopamine-dependent signs in parkinsonian syndromes: evaluation and results].
With dopaminergic systems, non dopaminergic neurotransmission probably plays a major role in parkinsonian syndromes (Multiple System Atrophy, Progressive Supranuclear Palsy, Pure Autonomic Failure, Cortical basal degeneration, Lewy Body Disease). A better understanding of the pathophysiology of these syndromes led to the development of molecules that interact with non dopaminergic systems. Thus, freezing, gait and balance disorders, dysautonomia and neuropsychiatric disorders are likely to benefit from specific treatments. However, due to methodological difficulties related to the evaluation of such molecules, controlled trials are rather rare and the results are often partial and sometimes unclear.
Tardieu
S
S
Cellule d'Evaluation Médicale, Assistance Publique, Hôpitaux de Marseille.
Becker
H
H
Micallef
J
J
Blin
O
O
D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use*; D003704:Dementia / Q000188:drug therapy* / Q000209:etiology*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology*; D004298:Dopamine / Q000378:metabolism*; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D009069:Movement Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D020734:Parkinsonian Disorders / Q000150:complications* / Q000175:diagnosis / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D009435:Synaptic Transmission / Q000502:physiology; D016896:Treatment Outcome
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins; D002800:Cholinesterase Inhibitors; D003024:Clozapine; D004298:Dopamine; D018698:Glutamic Acid; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors